Cited by 357Antibiotic Resistance in BacteriaBacterial Genetics and BiotechnologyAntibiotics Pharmacokinetics and Efficacy

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa

Open access

Ito, Akinobu, Nishikawa, Toru, Matsumoto, Shuhei, Yoshizawa, Hidenori, Sato, Takafumi, Nakamura, Rio, Tsuji, Masakatsu, Yamano, Yoshinori·2016·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.01405-16PMC PMC5119021

Open this paper in CoChat — free account

Abstract

Cefiderocol (S-649266) is a novel parenteral siderophore cephalosporin conjugated with a catechol moiety at the third-position side chain. The in vitro activity of cefiderocol against Pseudomonas aeruginosa was enhanced under iron-depleted conditions, whereas that of ceftazidime was not affected. The monitoring of [thiazole- 14 C]cefiderocol revealed the increased intracellular accumulation of cefiderocol in P. aeruginosa cells incubated under iron-depleted conditions compared with those incubated under iron-sufficient conditions. Cefiderocol was shown to have potent chelating activity with ferric iron, and extracellular iron was efficiently transported into P. aeruginosa cells in the presence of cefiderocol as well as siderophores, while enhanced transport of extracellular ferric iron was not observed when one of the hydroxyl groups of the catechol moiety of cefiderocol was replaced with a methoxy group. We conclude that cefiderocol forms a chelating complex with iron, which is actively transported into P. aeruginosa cells via iron transporters, resulting in potent antibacterial activity of cefiderocol against P. aeruginosa .

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/aac.01405-16

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
ACETYLORNITHINASE OF ESCHERICHIA COLI: PARTIAL PURIFICATION AND SOME PROPERTIES
Vogel, H. J., & Bonner, D. M. (1956) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65874-0 · Cited by 4,001
Metallo-β-Lactamases: the Quiet before the Storm?
Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.306-325.2005 · Cited by 1,457
Comprehensive transposon mutant library of Pseudomonas aeruginosa
Jacobs, M. A., Alwood, A., Thaipisuttikul, I., Spencer, D. H., Haugen, E., Ernst, S., Will, O., Kaul, R., Raymond, C. K., Levy, R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036282100 · Cited by 1,129
Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance
Woodford, N., Turton, J. F., & Livermore, D. M. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00268.x · Cited by 881
Pseudomonas aeruginosa – a phenomenon of bacterial resistance
Strateva, T., & Yordanov, D. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.009142-0 · Cited by 803
Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
Bonomo, R. A., & Szabó, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504477 · Cited by 751
Current Epidemiology and Growing Resistance of Gram-Negative Pathogens
Livermore, D. M. (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.2.128 · Cited by 425
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
Of Pseudomonas, porins, pumps and carbapenems
Livermore, D. M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.3.247 · Cited by 393

Flagged first, then by citations

Show all 33 references

Research works printed but not linked: 4

Griffiths E. 1978. Iron in biological systems, p 1–27. In Bullen JJ, Griffiths E (ed), Iron and infection. John Wiley & Sons, New York, NY.
Nakamura R, Toba S, Tsuji M, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin. IV: in vivo efficacy in various murine infection models, abstr F1-1558. Abstr 54th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.
Nakamura R, Toba S, Ito A, Tsuji M, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin. V: pharmacodynamic assessment in murine thigh infection models, abstr F1-1559. Abstr 54th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.
Müller C, Hofer B, Desarbre E, Page MGP. 2010. Enhanced activity of the siderophore monosulfactam BAL30072 (BAL) against Acinetobacter in iron-limited conditions, abstr F1-2133. Abstr 50th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.

Sorted by citations

Items 201–300 of 357

Worldwide trend discovery of structural and functional relationship of metallo-β-lactamase for structure-based drug design: A bibliometric evaluation and patent analysis
Azman, A. A., Leow, T. C., Noor, N. D. M., Noor, S. A. M., Latip, W., & Ali, M. S. M. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128230 · Cited by 13
The antibiotic arms race: current and emerging therapy forKlebsiella pneumoniaecarbapenemase (KPC) - producing bacteria
Plazak, M. E., Tamma, P. D., & Heil, E. L. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1538354 · Cited by 12
Dirhodium (II) complex interferes with iron-transport system to exert antibacterial action against Streptococcus pneumoniae
Yang, X.-Y., Xu, J., Meng, M., Li, N., Liu, C.-Y., & He, Q. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.11.021 · Cited by 12
Erratum to: In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
Naas, T., Lina, G., Henriksen, A. S., Longshaw, C. M., & Jehl, F. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab102 · Cited by 12
Location, Location, Location: Establishing Design Principles for New Antibacterials from Ferric Siderophore Transport Systems
Luo, V. C., & Peczuh, M. W. (2024) · Molecules · doi:10.3390/molecules29163889 · Cited by 11
Discovery of a fluorinated macrobicyclic antibiotic through chemical synthesis
Tresco, B. I. C., Wu, K. J. Y., Ramkissoon, A., Aleksandrova, E. V., Purdy, M., See, D. N. Y., Liu, R. Y., Polikanov, Y. S., & Myers, A. G. (2025) · Nature Chemistry · doi:10.1038/s41557-025-01738-7 · Cited by 11
Dark Red Urine in a Patient on Cefiderocol and Ferric Gluconate
Lewis, T. C., & Arnouk, S. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211070029 · Cited by 11
Does Cefiderocol Have a Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management?
Gavioli, E. M., Guardado, N., Haniff, F., Deiab, N., & Vider, E. (2021) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0602 · Cited by 11
New antibiotics for the treatment of nonfermenting Gram-negative bacteria
Bassetti, M., Russo, C., Vena, A., & Giacobbe, D. R. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000757 · Cited by 11
Discovery of YFJ-36: Design, Synthesis, and Antibacterial Activities of Catechol-Conjugated β-Lactams against Gram-Negative Bacteria
Liu, F., Kou, Q., Li, H., Cao, Y., Chen, M., Meng, X., Zhang, Y., Wang, T., Wang, H., Zhang, D., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00265 · Cited by 10
Detection and characterisation of 16S rRNA methyltransferase-producing Pseudomonas aeruginosa from the UK and Republic of Ireland from 2003–2015
Taylor, E., Jauneikaite, E., Sriskandan, S., Woodford, N., & Hopkins, K. L. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106550 · Cited by 10
High-Throughput Discovery of Synthetic Siderophores for Trojan Horse Antibiotics
Weber, B. S., Ritchie, N. E., Hilker, S., Chan, D. C. K., Peukert, C., Deisinger, J. P., Ives, R., Årdal, C., Burrows, L. L., Brönstrup, M., et al. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00359 · Cited by 9
Vectorization via Siderophores Increases Antibacterial Activity of K(RW) 3 Peptides against Pseudomonas aeruginosa
Olshvang, E., Fritsch, S., Scholtyssek, O. C., Schalk, I. J., & Metzler‐Nolte, N. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202300364 · Cited by 9
Dynamics of iron metabolism in patients with bloodstream infections: a time-course clinical study
Moro, H., Bamba, Y., Nagano, K., Hakamata, M., Ogata, H., Shibata, S., Cho, H., Aoki, N., Sato, M., Ohshima, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46383-7 · Cited by 9
New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties
Lombardi, A., Alagna, L., Palomba, E., Viero, G., Tonizzo, A., Mangioni, D., & Bandera, A. (2024) · Transplant International · doi:10.3389/ti.2024.11692 · Cited by 9
Oosporein Produced by Root Endophytic Chaetomium cupreum Promotes the Growth of Host Plant, Miscanthus sinensis, under Aluminum Stress at the Appropriate Concentration
Haruma, T., Doyama, K., Lu, X., Arima, T., Igarashi, T., Tomiyama, S., & Yamaji, K. (2022) · Plants · doi:10.3390/plants12010036 · Cited by 9
Cefiderocol in context
Huttner, A. C. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30615-7 · Cited by 9
Beta lactam
Iyer, R. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00212-7 · Cited by 9
Sonotheranostic nanosideromycin eradicates bacterial biofilm infections via ultrasound-detonated ROS generation and ferroptosis-like death
Pang, X., Zhang, C., Xiao, Q., Cheng, Y., Dai, Q., Hu, C., Tan, S., Liu, G., & Zeng, Y. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.09.020 · Cited by 8
Modified Galacto‐ or Fuco‐Clusters Exploiting the Siderophore Pathway to Inhibit the LecA‐ or LecB‐Associated Virulence of Pseudomonas aeruginosa
Madaoui, M., Vidal, O., Meyer, A., Noël, M., Lacroix, J.-M., Vasseur, J., Marra, A., & Morvan, F. (2020) · ChemBioChem · doi:10.1002/cbic.202000490 · Cited by 8
In vitro activity of cefiderocol against Gram-negative aerobic bacilli in planktonic and biofilm form–alone and in combination with bacteriophages
Pirlar, R. F., Halili, N., Travnik, T., Trampuž, A., & Karbysheva, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-01704-w · Cited by 8
Antibiotics targeting Gram-negative bacteria
Rangarajan, R., & Venkataraman, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818480-6.00003-5 · Cited by 8
In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany
Ghebremedhin, B., & Ahmad‐Nejad, P. (2021) · Pathogens · doi:10.3390/pathogens10101258 · Cited by 8
Pharma‐molecule Transport across Bacterial Membranes: Detection and Quantification Approaches by Electrochemistry and Bioanalytical Methods
Golubchik, A., Lopes, L. C., Singh, V., & Kuss, S. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202101055 · Cited by 8
Integrating bacterial molecular genetics with chemical biology for renewed antibacterial drug discovery
Parkhill, S. L., & Johnson, E. O. (2024) · Biochemical Journal · doi:10.1042/bcj20220062 · Cited by 7
β-Lactam antibiotics and β-lactamases: historical perspectives and a review of β-lactamase inhibitors derived from natural products
Moyo, P., Albert, I. O., Hlungwani, N., Sibanda, T., Lumu, P., Khorommbi, N. K., Kaur, G., Calvopiña, K., Siegwart, G., Buabeng, N. B., et al. (2026) · Natural Product Reports · doi:10.1039/d5np00081e · Cited by 7
Perspective Approaches to “Trojan Horse” Strategy Development for Combating Bacterial Pathogens
Shleeva, M. O., Kozobkova, N. V., Demina, G. R., & Kaprelyants, A. S. (2026) · Pharmaceuticals · doi:10.3390/ph19050701 · Cited by 7
In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal
Gijón-Cordero, D., García-Castillo, M., Fernández-López, M. D. C., Bou, G., Siller, M., Calvo, J., Pitart, C., Vilà, J., Torno, N., Gimeno, C., et al. (2023) · Revista Española de Quimioterapia · doi:10.37201/req/098.2023 · Cited by 7
Klinische Erfahrungen mit Cefiderocol
Witzke, O., & Brenner, T. (2022) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-022-00925-5 · Cited by 7
Enhancing Uptake of Antibiotics into Gram-Negative Bacteria Using Nonribosome-Targeting Aminoglycoside-Based Adjuvants
Schweizer, F. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0131 · Cited by 7
The Role of Bacterial Siderophores in Infection Therapy: From Anti-Infective Mechanisms to Therapeutic Advances
Xiao, J., Bu, Y., Tao, Y., Zhou, Z., Zou, J., Cui, W., & Yang, Z. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s576272 · Cited by 6
Loss of the ferripyochelin receptor FptA drives reduced cefiderocol susceptibility and impairs fitness in Pseudomonas aeruginosa PA14
Kang, D., Baptista, R. P., Drusin, S. I., Moreno, D. M., Arias, C. A., & Miller, W. R. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01410-25 · Cited by 6
A Selective Culture Medium for Screening Cefiderocol Resistance in Enterobacterales , Pseudomonas aeruginosa, and Acinetobacter baumannii
Ibrahim, A., Bouvier, M., Sadek, M., Decousser, J., Poirel, L., & Nordmann, P. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.01883-22 · Cited by 6
Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
Woods, B. S., Schmitt, L. H. M., Janković, D., Kearns, B., Scope, A., Ren, S., Srivastava, T., Ku, C.-C., Hamilton, J., Rothery, C., et al. (2024) · Health Technology Assessment · doi:10.3310/ygwr4511 · Cited by 6
Efficient Single‐Pot Synthesis of Thiazole Derivatives: A Synoptic View
Ramyashree, N., Lokesh Kumar, S., Tabassum, S., Chundattu, S. J., & Govindaraju, S. (2025) · ChemistrySelect · doi:10.1002/slct.202404789 · Cited by 6
Post-market safety profile of cefiderocol: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)
Lin, H., Chen, Z., Liu, S., Bi, Y., Hu, J., & Ju, M. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00894-3 · Cited by 6
Exploring Antibiotic-Potentiating Effects of Tobramycin–Deferiprone Conjugates in Pseudomonas aeruginosa
Gandhi, K., Dhiman, S., Arora, R., Ramirez, D. M., Ramirez, D., Arthur, G., & Schweizer, F. (2023) · Antibiotics · doi:10.3390/antibiotics12081261 · Cited by 6
A Glance on the Role of Bacterial Siderophore from the Perspectives of Medical and Biotechnological Approaches
AlMatar, M., Albarri, O., Makky, E. A., Var, İ., & Köksal, F. (2020) · Current Drug Targets · doi:10.2174/1389450121666200621193018 · Cited by 10
Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens
Jorda, A., & Zeitlinger, M. A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917375 · Cited by 6
Role of the drug efflux pump in the intrinsic cefiderocol resistance of Pseudomonas aeruginosaPreprint
Ikawa, S., Yamasaki, S., Morita, Y., & Nishino, K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.31.494263 · Cited by 6
Deciphering the Mechanism of Action of a Short, Synthetic Designer AMP Against Gram‐Negative Bacteria
Shadangi, S., Singh, A. P., & Rana, S. (2025) · Biopolymers · doi:10.1002/bip.70019 · Cited by 5
Unraveling the mechanisms behind the enhanced efficacy of β-lactam-based sideromycins
Lacasse, E., Binette, R., Guibout, H., Liu, R., Lin, Y., Ghosh, M., Boudreault, P., Miller, M. J., & Malouin, F. (2025) · Communications Biology · doi:10.1038/s42003-025-08898-9 · Cited by 5
The hidden link between cefiderocol resistance and increased virulence in Klebsiella pneumoniae: insights from a transposon-directed insertion-site sequencing-based investigation
Müller, J. U., Eger, E., Jana, B., Schwabe, M., Nurjadi, D., Ma, Y., Pirolo, M., Guardabassi, L., & Schaufler, K. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.12.010 · Cited by 5
On the coordination chemistry of a bacterial siderophore cepabactin from a theoretical perspective
Antony, A., Thomas, T., & Augustine, C. (2023) · Journal of Molecular Modeling · doi:10.1007/s00894-023-05565-w · Cited by 6
Insights into the activity of cefiderocol against PER-2 producing Enterobacterales
Ruggiero, M., Muñoz, I. B., Gutkind, G., Hujer, A. M., Bonomo, R. A., & Power, P. P. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01720-23 · Cited by 5
Potential Use of Cefiderocol and Nanosilver in Wound Dressings to Control Multidrug-Resistant Gram-Negative Bacteria
Binert-Kusztal, Ż., Krakowska, A., Skiba‐Kurek, I., Luty–Błocho, M., Kula, A., Olechowska‐Jarząb, A., Dorożyński, P., & Skalski, T. (2025) · Molecules · doi:10.3390/molecules30153072 · Cited by 5
Distinct chromosomal mutation associated with cefiderocol resistance in Acinetobacter baumannii: a combined bioinformatics and mass spectrometry approach to unveil and validate the in vivo-acquired chemoresistance
Morosi, L., Golzato, D., Bussini, L., Guma, H., Tordato, F., Armanini, F., Asif, Z., Carella, F., Morelli, P., Bartoletti, M., et al. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1480322 · Cited by 4
Siderophore cephalosporins
Page, M. G. P. (2025) · EcoSal Plus · doi:10.1128/ecosalplus.esp-0015-2022 · Cited by 4
Cefiderocol therapy among immunocompromised adult patients: a descriptive analysis from a prospective, multicentre cohort study
Lombardi, A., Giacobbe, D. R., Mangioni, D., Mariani, B., Muscatello, A., Muccio, M., Aldieri, C., Briano, F., Cacopardo, B. S., Calabresi, A., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11573-3 · Cited by 4
The Therapeutic Potential of Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Narrative Review
Złotowska, A., Buzun, W. H., Pełka, K., Zalewska, Z., & Duszyńska, W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238415 · Cited by 4
Mechanisms and Therapeutic Potential of Nutritional Immunity
Ugwu, C. E., Akinsulie, O. C., Ayandokun, T. F., Ajibade, F. A., Shahzad, S., Aliyu, V. A., Oladoye, M. J., Idris, I., Obasi, K. O., Edeh, J. K., et al. (2026) · Pathogens · doi:10.3390/pathogens15020176 · Cited by 4
Positron Emission Tomography Imaging of Bacterial Infections With an Enterobactin Analog to Monitor Treatment Efficacy With a Catechol Antibiotic
Joaqui‐Joaqui, M. A., Tran, P. N., Marlin, A., Armstrong‐Pavlik, F., Cao, M., Pierre, V. C., & Boros, E. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.2391261 · Cited by 4
Mechanisms involved in cefiderocol resistance in French Pseudomonas aeruginosa clinical strains
GAUTHIER, E., PISANI, M., Bour, M., Grosjean, M., Plésiat, P., Safari, S., Hartkoorn, R. C., SOURO, L., Prétot, E., & Jeannot, K. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00520-26 · Cited by 4
In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17
Wohlfarth, E., Kresken, M., Deuchert, F., Gatermann, S. G., Pfeifer, Y., Pfennigwerth, N., Seifert, H., Higgins, P. G., Werner, G., & Study Group ‘Antimicrobial Resistance‘ of the Paul Ehrlich Society for Infection Therapy (2023) · Antibiotics · doi:10.3390/antibiotics12050864 · Cited by 4
Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Cefiderocol in Chinese Healthy Subjects
Zhang, C., Yu, S., Li, S., Wu, X., Wei, Q., He, J., Cao, G., Yang, H., Wang, J., Fujitani, K., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03147-1 · Cited by 4
Current status of countermeasures for infectious diseases and resistant microbes in the field of urology
Kitano, H., Teishima, J., Shigemura, K., Ohge, H., Fujisawa, M., & Matsubara, A. (2019) · International Journal of Urology · doi:10.1111/iju.14087 · Cited by 4
Thiazoles
Chotera‐Ouda, A., Wróblewska, A., Tokarz, P., & Stevens, C. V. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818655-8.00129-3 · Cited by 4
Biofilm-associated Achromobacter xylosoxidans prosthetic valve infective endocarditis
Wackernagel, L.-M., Kikhney, J., Kruis, T., Menzel, P., Schneider, M., Grubitzsch, H., Gogolok, J., Sander, L. E., Kurth, F., Moter, A., et al. (2025) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2025.151664 · Cited by 3
The iron-infection axis revisited: From mechanistic insights to therapeutic frontiers
Moro, H. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102818 · Cited by 3
Vitamin B12 promotes cefiderocol resistance and small-colony variants in carbapenem-resistant Acinetobacter baumannii
Mezcord, V., Luu, I., Akhtar, U., Traglia, G. M., Rodriguez, C., Moheb, S., Sanchez, S. D., Soto, M. T., Clave, M. J. C., Sieira, R., et al. (2026) · mBio · doi:10.1128/mbio.03760-25 · Cited by 3
Siderophore–Porphyrin conjugates for bacteria-selective antimicrobial photodynamic therapy
Oh, J., Choi, S., Yang, W., Choi, J., & Seo, J. (2026) · Medicinal Chemistry Research · doi:10.1007/s00044-026-03537-2 · Cited by 3
Single Molecule Non-cleavable Multiply Active Antibacterials
Bremner, J. B. (2021) · Springer eBooks · doi:10.1007/978-981-16-0999-2_3 · Cited by 3
Significant Publications on Infectious Diseases Pharmacotherapy in 2020
Eubank, T. A., Zaidan, N., Alnezary, F. S., Moc, C., Olson, K., Zaki, A. F., McDaneld, P. M., Gonzales-Luna, A. J., & on behalf of the Houston Infectious Diseases Network (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211040438 · Cited by 3
Construction and Performance Research of Reinforced Iron-Based Powder Metallurgy Materials Based on Phyllanthin as Drug Transport Carriers
Feng, X., Tao, A., & Song, Z. (2022) · Advances in Materials Science and Engineering · doi:10.1155/2022/8528074 · Cited by 3
Retracted
Evaluation of In vitro Activity of Cefiderocol and Ceftolozane-Tazobactam against Extended-Spectrum β-Lactamase–Producing Coliform and Multidrug Resistant Acinetobacter baumannii and Pseudomonas aeruginosa
Hegazy, E. E., Zahra, S., Shoeib, S. M., & Taha, M. S. (2022) · The Egyptian Journal of Medical Microbiology · doi:10.21608/ejmm.2022.262698 · Cited by 3
Evaluation of the Stereochemistry of Staphyloferrin A for Developing Staphylococcus‐Specific Targeting Conjugates
Wang, T. A., Chen, P.-L., Chen, Y.-C. S., Chiu, Y., Lin, Z.-J., Kao, C.-Y., & Hung, H.-M. (2024) · ChemBioChem · doi:10.1002/cbic.202400480 · Cited by 3
New and Novel Agents Targeting Resistant Gram-Negative Bacteria: A Review for the Clinical Microbiologist
Mitchell, S. L., & Humphries, R. M. (2018) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2018.08.007 · Cited by 3
Antibiotic Consideration in Transplant Recipients
Altshuler, J., Aitken, S. L., Maslow, M. J., Papadopoulos, J., & Safdar, A. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_50 · Cited by 3
Synthetic strategies in construction of organic low molecular-weight carrier-drug conjugates
Skwarecki, A. S., Nowak, M. G., & Milewska, M. J. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104311 · Cited by 3
Catechol-substituted siderophore colistin exhibits superior antimicrobial activity than its unmodified polypeptide counterpart
Bescós‐Ramo, S., Gámez, E., Encabo-Berzosa, M. D. M., Piñol, M., Oriol, L. T., & Arruebo, M. (2025) · BMC Chemistry · doi:10.1186/s13065-025-01538-7 · Cited by 2
In vitro activity of cefiderocol against carbapenem-resistant Gram-negative pathogens in Japan
Matsui, K., Sakurai, A., Matsumura, Y., Hosoda, T., Suzuki, M., Saito, S., Hase, R., Kato, H., Hashimoto, T., Matono, T., et al. (2026) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2026.102905 · Cited by 2
Activity of novel antibiotics against dual metallo-Beta-lactamase producing Enterobacter hormaechei clinical isolates
Solar, C., Díaz, L., Soto, K., Martínez, J. R. W., Canales, N., Bergman, Y., Peters, A., Rafael Araos, B., García, P., Tamma, P. D., et al. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf252 · Cited by 2
Novel antibacterials targeting multidrug-resistant gram-positive and gram-negative bacteria: an updated review
Özdemir, Y. E., Sürme, S., Özdemir, M. Ş., & Mustafayev, K. (2026) · Future Microbiology · doi:10.1080/17460913.2026.2661277 · Cited by 2
Innovative Antibiotics: The Experience of Cefiderocol in Carbapenem-Resistant Gram-Negative Infections
Melchio, M., Briano, F., Sepulcri, C., Vena, A., & Bassetti, M. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s541581 · Cited by 2
Combinatorial effects of a novel SHV-248 variant, NDM-5, and ompK35 deficiency drive high-level cefiderocol resistance in Klebsiella pneumoniae
Zhao, C., Liu, Y., Hong, H., Yun, C., Dai, X., Dai, Q., Wei, D., & Liu, Y. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00026-26 · Cited by 2
Cefiderocol susceptibility in carbapenem-resistant Acinetobacter baumannii , Pseudomonas aeruginosa , and Stenotrophomonas maltophilia isolates: concordance of disk diffusion with the reference method and comparative analysis of CLSI-EUCAST criteria
Saylam, E., Cetin, B., Kalem, F., Dağı, H. T., & Maçin, S. (2026) · Journal of Chemotherapy · doi:10.1080/1120009x.2026.2679800 · Cited by 2
Intrinsic resistance networks shape cefiderocol susceptibility in ST258 Klebsiella pneumoniae
Rome, K., Terlecky, A. J., Yen, K. K., Long, T., Bucich, M. J., Thom, K. V., Shashkina, E., Chen, L., & Kreiswirth, B. N. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00197-26 · Cited by 2
Tetrapyrrolic metal complexes and functional materials in antimicrobial photodynamic therapy: From molecular targeting and excited-state dynamics to clinical translation
Barczyk, D., Płaskonka, D. M., Repetowski, P., Warszyńska, M., & Dąbrowski, J. M. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.218272 · Cited by 2
Antisense oligonucleotides: design, implementation and future perspectives in microbiology
Kelly, J. B., Brodie, G., & Zeden, M. S. (2026) · Current Opinion in Microbiology · doi:10.1016/j.mib.2026.102794 · Cited by 2
Evaluations of FDA-approved Drugs Targeting 3CLP of SARS-CoV-2 Employing a Repurposing Strategy
Ahmad, S. S., & Khalid, M. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220816125639 · Cited by 2
Clinical Appraisal of Cefiderocol in the Treatment of Non-fermenting Gram-Negative Bacilli
McLeod, C. C., Tan, K. K., Kebriaei, R., & Abdul‐Mutakabbir, J. C. (2023) · Current Infectious Disease Reports · doi:10.1007/s11908-023-00800-0 · Cited by 2
Cefiderocol: a first and novel class of siderophore cephalosporin for Carbapenem-resistant Gram-negative infection
Yamano, Y., Morita, I., & Ariyasu, M. (2024) · Folia Pharmacologica Japonica · doi:10.1254/fpj.24029 · Cited by 2
Self-citation
Pharma‐molecule Transport across Bacterial Membranes: Detection and Quantification Approaches by Electrochemistry and Bioanalytical Methods
Golubchik, A., Lopes, L. C., Singh, V., & Kuss, S. (2021) · Angewandte Chemie · doi:10.1002/ange.202101055 · Cited by 2
Siderophore‑antibiotic conjugates: structural diversity and antibacterial activity
Chernyshov, V. V., Kuzovlev, A., Cherepanova, N. D., Kasatkina, M. A., & Ivanov, R. A. (2022) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2022.4.314-344 · Cited by 2
An Overview of the Activities of Cefiderocol Against Sensitive and Multidrug- Resistant (MDR) Bacteria
AlMatar, M., Albarri, O., Makky, E. A., Var, İ., & Köksal, F. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666200818211405 · Cited by 2
Iron metabolism in bacterial cells: from physiological significance to a new class of antimicrobial agents
Kozlov, A. V., Lyamin, A. V., Zhestkov, A. V., Gusyakova, O. A., & Khaliulin, A. V. (2022) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2022.2.165-170 · Cited by 2
Anti-Bacterial Agents
López-Jácome, L. E., Mercado-Casillas, Y. M., Méndez-Sotelo, B. J., Jiménez-Cortés, J. G., Tovar-García, A., Estrada-Velasco, Á. Y., Villegas, J. Á. A., Martínez, J. D. P., & García‐Contreras, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00186-5 · Cited by 2
Trojan Horses: Conjugating Siderophores and Antibiotics—A New Approach to Treating Pseudomonas aeruginosa Infection
Xiao, W., Ma, X., Liu, D., Li, S., Cheng, J., & Lin, J. (2026) · Microorganisms · doi:10.3390/microorganisms14040891 · Cited by 1
Genomic analysis reveals multi-level resistance network linking oxidative stress pathway mutations to cefiderocol resistance and clonal evolution in Klebsiella pneumoniae from the United Arab Emirates
Daoud, L., Collyns, T., Ghazawi, A., & Al-Marzooq, F. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1820198 · Cited by 1
Experimental methods for evaluating siderophore–antibiotic conjugates
Motz, R. N., Kamyabi, G., & Nolan, E. M. (2024) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2024.06.004 · Cited by 1
Phylogenomics-driven metalloantibiotic engineering: Overcoming ciprofloxacin resistance in Pseudomonas aeruginosa with sideromycin-bismuth synergy
Chen, J., Pan, J., Lu, X., Wang, L., Tan, K., Yue, Y., Gu, L., Wang, S., Chen, M., Jiang, H., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102637 · Cited by 1
The in vitro activity of aztreonam-avibactam and cefiderocol against globally collected clinical metallo-β-lactamase- and/or serine-carbapenemase-positive Enterobacterales isolates and the utility of commonly used in vitro diagnostic kits
Estabrook, M., Streit, C., Townsend, A. I., Stone, G., Kamat, S., & Sahm, D. F. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03820-25 · Cited by 1
ZIP14-VDAC2 mediates the transport of extracellular iron into mitochondria in hepatocytes under PFOS exposure
Li, Y., Yu, M., Ren, J., Qiu, T., Zhang, J., Wu, C., Bai, J., Sun, X., & Yao, X. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112108 · Cited by 1
Genomic and Clinical Features Associated With Reduced Susceptibility to Cefiderocol and Cross-Resistance to β-Lactam/β-Lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa
Egge, S. L., Kang, D., Pouya, N., Thornton, P. C., Flores, E. M., Clarke, K., Adelman, M. W., Rosenbaum, C. L., Baptista, R. P., Arias, C. A., et al. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag263 · Cited by 1
Evidence of cefiderocol-persistence in Pseudomonas aeruginosa in vitro biofilms and in a murine infection model
Mangiaterra, G., Lucidi, M., Piccioni, G., Rosa, R., Gugliandolo, D., Fino, I. D., Rossano, M., Vignaroli, C., Visca, P., Bragonzi, A., et al. (2026) · Biofilm · doi:10.1016/j.bioflm.2026.100370 · Cited by 1
Update on the comparative in vitro activity of cefiderocol and four β-lactam–β-lactamase-inhibitor combinations against clinically important Gram-negative pathogens
Wohlfarth, E., Deuchert, F., Gatermann, S. G., Higgins, P. G., Pfeifer, Y., Pfennigwerth, N., Seifert, H., Werner, G., Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Infection Therapy, Becker, S., et al. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag103 · Cited by 1
Iron-acquisition–targeted therapy for multidrug-resistant Klebsiella pneumoniae: siderophore–antibiotic conjugates, clinical evidence, and emerging resistance
Afzaruddin, S. S., Ishak, N. H., Hamid, S. B. S., Ismail, Z., & Shabani, N. R. M. (2026) · Biochimie · doi:10.1016/j.biochi.2026.06.014 · Cited by 1
Large-scale discovery platform enables identification of peptides targeting drug-resistant candidiasis
Behsaz, B., Adduri, A., Güler, M., Mohamed, O. G., Caraballo‐Rodríguez, A. M., Chaudhary, N. K., Krummenacher, B., Miller, C., Liu, S., Zamith‐Miranda, D., et al. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101510 · Cited by 1
Molecular and epidemiological characteristics of cefiderocol-resistant Klebsiella pneumoniae: Insights from genomic analysis
Jia, X., Long, S., Li, Y., Yang, J., Mao, H., Li, C., Li, D., & Zhang, J. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107916 · Cited by 1
Modular Inhibitor Approach to Map the Catalytic Trajectory of an Iterative Siderophore Synthetase, DesD
Merrick, C. E., Patel, K. D., Kalita, P., Gulati, N. M., Gulick, A. M., & Wencewicz, T. A. (2026) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.6c00078 · Cited by 1

Authors: Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y.
Affiliations: Shionogi (Japan) (JP)
Corresponding author: Ito, Akinobu
ORCID: Matsumoto, Shuhei
Yoshizawa, Hidenori
Sato, Takafumi
Nakamura, Rio
Yamano, Yoshinori
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2016-12
Volume: 60
Issue: 12
Pages: 7396-7401
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.01405-16
PMC: PMC5119021
OpenAlex: W2530661320
Cited by: 352
References: 33
Citations by year: 2026: 52 · 2025: 34 · 2024: 35 · 2023: 37 · 2022: 40 · 2021: 37 · 2020: 41 · 2019: 29 · 2018: 30 · 2017: 16 · 2016: 1
FWCI: 12.36
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Keywords: cefiderocol, siderophore cephalosporin, Pseudomonas aeruginosa, iron chelation, catechol moiety, iron depletion, intracellular accumulation, iron transporters, antibacterial activity, ceftazidime
MeSH terms: Cefiderocol, Anti-Bacterial Agents, Biological Transport, Carbon Radioisotopes, Ceftazidime, Cephalosporins, Fluoresceins, Fluorescent Dyes, Iron, Iron Chelating Agents, Microbial Sensitivity Tests, Pseudomonas aeruginosa, Structure-Activity Relationship, Thiazoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks